

# Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over

Information for the public

Published: 30 July 2025

[www.nice.org.uk](http://www.nice.org.uk)

Vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) is available on the NHS as a possible treatment for cystic fibrosis. It is for people 6 years and over who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

If you are not eligible for vanzacaftor-tezacaftor-deutivacaftor but are already having it, you should be able to continue until you and your healthcare professional decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on cystic fibrosis](#) may be a good place to find out more.

The [Cystic Fibrosis Trust](#) (0300 373 1000) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7127-5